Albendazole is a benzimidazole anthelmintic, active against most nematodes and some cestodes. It is used in the treatment of intestinal nematode infections and in higher doses in the treatment of hydatid disease. Albendazole exhibits vermicidal, ovicidal, and larvicidal activity. The principal mode of action of Albendazole is its inhibitory effect on tubulin polymerization, which results in the loss of cytoplasmic microtubules.
Child (12 to 24 months): 200 mg as a single dose (Half of Albendazole 400 tablet or 5 ml Albendazole suspension).
Adults & children (over two years): 400 mg (400 tablet or 10 ml Albendazole suspension) as a single dose in cases of Enterobius vermicularis, Trichuris trichiura, Ascaris lumbricoides, Ancylostoma duodenale and Necator americanus.
In cases of strongyloidiasis or taeniasis, 400 mg (400 mg tablet or 10 ml suspension) as a single dose should be given for three consecutive days.
Giardiasis: 400 mg (400 mg tablet or 10 ml suspension) once daily for five days.
Albendazole in hydatid disease (Echinococcosis): In the treatment of echinococcosis, Albendazole is given by mouth with meals in a dose of 400 mg twice daily for 28 days for patients weighing over 60 kg. A dose of 15 mg/kg body weight daily in two divided doses (to a maximum total daily dose of 800 mg) is used for patients weighing less than 60 kg. For cystic echinococcosis the 28-days course may be repeated after 14 days without treatment to a total of three treatment cycles. For alveolar echinococcosis, cycles of 28 days of treatment followed by 14 days without treatment may need to continue for months or years. When three courses of therapy have been given in the pre or post surgical setting, optimal killing of cyst contents is achieved.